Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133670837> ?p ?o ?g. }
- W2133670837 endingPage "2428" @default.
- W2133670837 startingPage "2425" @default.
- W2133670837 abstract "Current management in acute myeloid leukemia (AML) includes induction chemotherapy followed by several courses of consolidation chemotherapyorallogeneicstem-cell transplantation(SCT).Theexpression 7 3 stands for a combination of intravenous chemotherapy that includes 7 days of cytarabine (AraC; 100 mg/m per day by continuous infusion) and 3 days of daunorubicin (DNR; 45 mg/m per day, given on days 1, 2, and 3). A series of pre-1985 studies by the Cancer and Leukemia Group B established 7 3 as the standard induction regimen for newly diagnosed AML. In addition, a DNR dose of 45 mg/m per day (DNR 45) was superior to DNR 30 mg/m per day (DNR 30) in the 7 3 regimen, with respect to achievement of complete remission (CR) in patients younger than age 60 years. Increasing the dose of AraC to 200 mg/m per day, extending its infusion period to 10 days (10 3), or the addition of oral thioguanine 100 mg/m twice per day on days 1 to 7 (7 3 7) did not additionally improve the results. CR rates for 7 3 ranged from 53% to 58%, were higher in younger patients (59% to 72% v 31% to 45% for patients older than age 60 years), and were maintained over the long term in less than 15% of patients. The value of postremission therapy was also recognized early, underscoring the fact that achievement of CR with current chemotherapy is not enough to cure AML. Through the years, many studies have been conducted with the intent to improve on 7 3. Substituting other anthracyclines for DNR on days 1, 2, and 3 suggested that some anthracyclines might be better than others. Mitoxantrone 8 to 12 mg/m per day compared with DNR 30 to 50 gave higher CR rates in some studies but not in others. In one of these studies, DNR 50, mitoxantrone 12 mg/m per day, and idarubicin (IDA) 10 mg/m per day displayed similar activity. However, the preponderance of current evidence favors IDA 12 to 13 mg/m per day compared with DNR 45 to 50 in terms of both CR rates (70% to 80% v 58% to 59%) and possibly survival. More recently, on the basis of earlier indications, doubling the dose of DNR to 90 mg/m per day for 3 days (DNR 90) was shown to induce significantly higher CR rates, compared with DNR 45, in select subsets of young (age 60 years or younger; 71% v 57%) and older (age 60 years and older; 64% v 54%) patients. These studies also demonstrated better overall survival for a subgroup of younger patients (younger than age 50 years or age 60 to 65 years) who were treated with DNR 90. A more recent study confirmed the results by Fernandez et al, in that the advantage of DNR 90 compared with DNR 45 was restricted to patients with an intermediate-risk karyotype and was less apparent in those with an unfavorable karyotype or high-risk molecular profile. The study by Lowenberg et al suggested that DNR 90 also benefitted patients with a favorable karyotype. Amsacrine and gemtuzumab ozogamicin (GO) have also been compared to DNR, in the context of a 7 3 strategy, with an advantage seen with the former but not the latter. In a nonrandomized comparison, both fludarabine and topotecan were shown to be inferior to DNR as induction partners to AraC. Similarly, no additional benefit was gained by adding a third drug to 7 3, including etoposide (75 mg/m per day on days 1 through 7), myeloid growth factors, P-glycoprotein modulator (PSC833), or GO, although the addition of GO might have benefitted patients with a favorable karyotype. Dose-intensification of 7 3 has also been attempted for AraC; a dose increase to 4 g/m per day or 6 g/m per day did not result in improved CR rates but might have prolonged remission duration without affecting overall survival. Highdose AraC has also been incorporated as part of a double induction strategystartingonday21withoutaffectingCRoroverall survival. The use of high-dose AraC and granulocyte colony-stimulating factor (GCSF) in combination with fludarabine was not superior to high-dose AraC plus G-CSF, but the possibility was recently noted that AraC plus G-CSF in combination with fludarabine plus IDA might perform better. In the article that accompanies this editorial, Holowiecki et al report on a large (n 652) multicenter trial of young patients (age 60 years or younger) with AML (excluding acute promyelocytic leukemia) who were randomly assigned to receive 7 3 alone (DA), or DA with a 3-hour infusion of cladribine (5 mg/m per day on days 1 through 5; DAC), or DA with a 30-minute infusion of fludarabine (25 mg/m per day on days 1 through 5). The corresponding CR rates were 56%, 68%, and 59%, in favor of DAC (P .01). Consolidation chemotherapy included high-dose AraC followed by SCT or 2-year maintenance chemotherapy, determined on the basis of risk of relapse. Three-year overall survival rates were 45% for DAC, 33% for DA (P .02), and 35% for DA plus fludarabine; leukemia-free survival and toxicity were not significantly different between the three arms. The outcome advantage for DAC was also apparent in patients with an unfavorable karyotype and possibly for those with a favorable karyotype. The results from the current Polish study confirm the authors’ initial observations comparing DAC to DA in the treatment of newly diagnosed AML and are also consistent with recent information on the anti-AML therapeutic value of clofarabine, a structurally JOURNAL OF CLINICAL ONCOLOGY E D I T O R I A L VOLUME 30 NUMBER 20 JULY 1" @default.
- W2133670837 created "2016-06-24" @default.
- W2133670837 creator A5016216479 @default.
- W2133670837 creator A5071977576 @default.
- W2133670837 date "2012-07-10" @default.
- W2133670837 modified "2023-10-06" @default.
- W2133670837 title "Going Beyond 7 + 3 Regimens in the Treatment of Adult Acute Myeloid Leukemia" @default.
- W2133670837 cites W1143126211 @default.
- W2133670837 cites W118967028 @default.
- W2133670837 cites W1481564836 @default.
- W2133670837 cites W1492445977 @default.
- W2133670837 cites W1519562949 @default.
- W2133670837 cites W1808968650 @default.
- W2133670837 cites W1823520599 @default.
- W2133670837 cites W1831246453 @default.
- W2133670837 cites W1857665725 @default.
- W2133670837 cites W1963335440 @default.
- W2133670837 cites W1965658643 @default.
- W2133670837 cites W1984229644 @default.
- W2133670837 cites W1985165035 @default.
- W2133670837 cites W1987612888 @default.
- W2133670837 cites W1993862617 @default.
- W2133670837 cites W1995900951 @default.
- W2133670837 cites W1996815004 @default.
- W2133670837 cites W2000896040 @default.
- W2133670837 cites W2005200801 @default.
- W2133670837 cites W2007386979 @default.
- W2133670837 cites W2011187792 @default.
- W2133670837 cites W2024544809 @default.
- W2133670837 cites W2025941747 @default.
- W2133670837 cites W2026067581 @default.
- W2133670837 cites W2027364921 @default.
- W2133670837 cites W2032982863 @default.
- W2133670837 cites W2033525557 @default.
- W2133670837 cites W2035661456 @default.
- W2133670837 cites W2039412651 @default.
- W2133670837 cites W2043938406 @default.
- W2133670837 cites W2065839959 @default.
- W2133670837 cites W2066151812 @default.
- W2133670837 cites W2069448515 @default.
- W2133670837 cites W2074425311 @default.
- W2133670837 cites W2079025304 @default.
- W2133670837 cites W2090858884 @default.
- W2133670837 cites W2100883771 @default.
- W2133670837 cites W2107029748 @default.
- W2133670837 cites W2112332290 @default.
- W2133670837 cites W2117844516 @default.
- W2133670837 cites W2119626196 @default.
- W2133670837 cites W2126572589 @default.
- W2133670837 cites W2127568389 @default.
- W2133670837 cites W2130011407 @default.
- W2133670837 cites W2133331792 @default.
- W2133670837 cites W2134350774 @default.
- W2133670837 cites W2138571761 @default.
- W2133670837 cites W2139717439 @default.
- W2133670837 cites W2141034604 @default.
- W2133670837 cites W2142830602 @default.
- W2133670837 cites W2148439987 @default.
- W2133670837 cites W2153994826 @default.
- W2133670837 cites W2158154670 @default.
- W2133670837 cites W2171484579 @default.
- W2133670837 cites W4237543851 @default.
- W2133670837 cites W4237785786 @default.
- W2133670837 cites W49953563 @default.
- W2133670837 doi "https://doi.org/10.1200/jco.2011.38.9601" @default.
- W2133670837 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22529263" @default.
- W2133670837 hasPublicationYear "2012" @default.
- W2133670837 type Work @default.
- W2133670837 sameAs 2133670837 @default.
- W2133670837 citedByCount "30" @default.
- W2133670837 countsByYear W21336708372012 @default.
- W2133670837 countsByYear W21336708372013 @default.
- W2133670837 countsByYear W21336708372015 @default.
- W2133670837 countsByYear W21336708372016 @default.
- W2133670837 countsByYear W21336708372017 @default.
- W2133670837 countsByYear W21336708372018 @default.
- W2133670837 countsByYear W21336708372020 @default.
- W2133670837 countsByYear W21336708372021 @default.
- W2133670837 countsByYear W21336708372022 @default.
- W2133670837 countsByYear W21336708372023 @default.
- W2133670837 crossrefType "journal-article" @default.
- W2133670837 hasAuthorship W2133670837A5016216479 @default.
- W2133670837 hasAuthorship W2133670837A5071977576 @default.
- W2133670837 hasBestOaLocation W21336708371 @default.
- W2133670837 hasConcept C126322002 @default.
- W2133670837 hasConcept C143998085 @default.
- W2133670837 hasConcept C177713679 @default.
- W2133670837 hasConcept C2778729363 @default.
- W2133670837 hasConcept C2779282312 @default.
- W2133670837 hasConcept C71924100 @default.
- W2133670837 hasConceptScore W2133670837C126322002 @default.
- W2133670837 hasConceptScore W2133670837C143998085 @default.
- W2133670837 hasConceptScore W2133670837C177713679 @default.
- W2133670837 hasConceptScore W2133670837C2778729363 @default.
- W2133670837 hasConceptScore W2133670837C2779282312 @default.
- W2133670837 hasConceptScore W2133670837C71924100 @default.
- W2133670837 hasIssue "20" @default.
- W2133670837 hasLocation W21336708371 @default.